RT Journal Article
SR Electronic
T1 Omicron COVID-19 Immune Correlates Analysis of a Third Dose of mRNA-1273 in the COVE Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.10.15.23295628
DO 10.1101/2023.10.15.23295628
A1 Zhang, Bo
A1 Fong, Youyi
A1 Fintzi, Jonathan
A1 Chu, Eric
A1 Janes, Holly E.
A1 Carpp, Lindsay N.
A1 Kenny, Avi
A1 Carone, Marco
A1 Benkeser, David
A1 van der Laan, Lars W. P.
A1 Deng, Weiping
A1 Zhou, Honghong
A1 Wang, Xiaowei
A1 Lu, Yiwen
A1 Yu, Chenchen
A1 Borate, Bhavesh
A1 Houchens, Christopher R.
A1 Martins, Karen
A1 Jayashankar, Lakshmi
A1 Huynh, Chuong
A1 Fichtenbaum, Carl J.
A1 Kalams, Spyros
A1 Gay, Cynthia L.
A1 Andrasik, Michele P.
A1 Kublin, James G.
A1 Corey, Lawrence
A1 Neuzil, Kathleen M.
A1 Priddy, Frances
A1 Das, Rituparna
A1 Girard, Bethany
A1 El Sahly, Hana M.
A1 Baden, Lindsey R.
A1 Donis, Ruben O.
A1 Koup, Richard A.
A1 Gilbert, Peter B.
A1 Follmann, Dean
A1 ,
A1 ,
A1 ,
A1 ,
YR 2023
UL http://medrxiv.org/content/early/2023/10/15/2023.10.15.23295628.abstract
AB In the coronavirus efficacy (COVE) phase 3 efficacy trial of the mRNA-1273 vaccine, IgG binding antibody (bAb) concentration against Spike (BA.1 strain) and neutralizing antibody (nAb) titer against Spike (BA.1 strain) pseudovirus were assessed as correlates of risk of Omicron COVID-19 and as correlates of relative boost efficacy in per-protocol recipients of a third (booster) dose. Markers were measured on the day of the boost (BD1) and 28 days later (BD29). For SARS-CoV-2 naive individuals, BD29 Spike IgG-BA.1 strain bAbs and BD29 BA.1-strain nAbs inversely correlated with Omicron COVID-19: hazard ratio (HR) per 10-fold marker increase [95% confidence interval (CI)] = 0.16 (0.03, 0.79); P=0.024 and 0.31 (0.10, 0.96); P = 0.042, respectively. These markers also inversely correlated with Omicron COVID-19 in non-naive individuals: HR = 0.15 (0.04, 0.63); P = 0.009 and 0.28 (0.07, 1.08); P = 0.06, trend. Fold-rise in markers from BD1 to BD29 had similarly strong inverse correlations. For SARS-CoV-2 naive individuals, overall booster relative (three-dose vs two-dose) efficacy was 46% (95% CI: 20%, 64%) and correlated with BA.1 strain nAb titer at exposure. At 56, 251, and 891 arbitrary units (AU)/ml (10th, 50th, and 90th percentile), the booster relative efficacies were −8% (95% CI: −126%, 48%), 50% (25%, 67%), and 74% (49%, 87%), respectively. Similar relationships were observed for Spike IgG-BA.1 strain bAbs and for the markers measured at BD29. The performance of bAb and nAb markers as correlates of protection against Omicron COVID-19 supports their continued use as surrogate endpoints for mRNA vaccination against Omicron COVID-19.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: W.D, H.Z., X.W., F.P., R.D., and B.G. are employed by Moderna Inc. and have stock or stock options in Moderna Inc. H.E.J. serves/served as an unpaid member within the past 36 months as a DSMB member for a Phase II monkeypox vaccine study (DMID) and for a Phase I oral cholera vaccine study (DMID). M.C. reports an honorarium for service within the past 36 months on a grant review panel for the National Comprehensive Cancer Network and Pfizer. C.J.F. reports grants to his institution within the past 36 months from Gilead Sciences, ViiV Healthcare, and Merck, as well as payment for advisory board participation within the past 36 months from ViiV Healthcare and Theratechnologies, Inc. K.M.N. reports grants to her institution within the past 36 months from Pfizer to conduct clinical trials of COVID-19 vaccines, but K.M.N. receives no salary support from these grants. K.M.N. reports a grant from Vaxco within the past 36 months for phase 1 testing of a broadly reactive COVID-19 vaccine. F.P. was a member of the CEPI Scientific Advisory Board within the past 36 months and reports support from Moderna, Inc. for attending meetings and/or travel within the past 36 months. Within the past 36 months, L.R.B. was involved in HIV and SARS-CoV-2 vaccine clinical trials conducted in collaboration with the NIH, HIV Vaccine Trials Network (HVTN), Covid Vaccine Prevention Network (CoVPN), International AIDS Vaccine Initiative (IAVI), Crucell/Janssen, Moderna, Military HIV Research Program (MHRP), the Gates Foundation, and Harvard Medical School; as well as participated on a DSMB for the NIH and an AMDAC Committee for the FDA. P.B.G. served as an unpaid member of the Moderna Zika Vaccine Scientific Advisory Board within the past 36 months. All authors declare no other support from any commercial entity for the submitted work; no other financial relationships with any commercial entities that might have an interest in the submitted work in the past 36 months, and no other relationships or activities within the past 36 months that could appear to have influenced the submitted work.Funding StatementAdministration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority Contracts No. 75A50120C00034 (P3001 study) and No. 75A50122C00013 (Immune Assays). National Institute of Allergy and Infectious Diseases of the National Institutes of Health grant R37AI054165 (PBG). National Institute of Allergy and Infectious Diseases of the National Institutes of Health grant UM1AI068635 (PBG). National Institute of Allergy and Infectious Diseases of the National Institutes of Health grant AI068614 (LC). National Cancer Institute, National Institutes of Health, Contract No. 75N91019D00024. National Institute of Allergy and Infectious Diseases of the National Institutes of Health grant 3UM1AI148575 (Baylor College of Medicine VTEU). The findings and conclusions herein are those of the authors and do not necessarily represent the views of the Department of Health and Human Services or its components. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The mRNA-1273-P301 study was conducted in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Good Clinical Practice guidelines, and applicable government regulations. The Central Institutional Review Board approved the mRNA-1273-P301 protocol and the consent forms. All participants provided written informed consent before enrollment. Central IRB services for the mRNA-1273-P301 study were provided by Advarra, Inc., 6100 Merriweather Dr., Suite 600, Columbia, MD 21044. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAccess to participant-level data and supporting clinical documents with qualified external researchers may be available upon request and is subject to review once the trial is complete.